Manchester-based drug discovery company C4X Discovery Holdings plc announced the appointment of Dr Cathy Tralau-Stewart, PhD, as chief scientific officer as of January 4, 2022.

“Cathy joins C4XD with more than 20 years of senior academic and industry leadership experience,” said the firm.

“Her broad and in-depth knowledge of drug discovery and translation of early research innovation into robust drug discovery programmes has enabled the development of scientific portfolios as well as the design and negotiation of many initiatives to support effective decision-making.

“Previously she was Senior Director, Alliances, for Takeda Pharmaceuticals where she was responsible for and contributed to the strategic development and management of academic alliances for Takeda for the US, Australia, Japan and Europe.

“Having started her career at GSK, she moved into academia where she held senior leadership roles building drug discovery portfolios through to Phase III clinical studies, at Imperial College London, University of California San Francisco and Stanford University-Takeda Alliance for Innovative Medicines.”

Cathy Tralau-Stewart